TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03039101
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill orally, daily, for 1 week
Study: NCT01228175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg look alike riboflavin tablets to match active study medication.
Study: NCT04448431
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/day capsules, orally
Study: NCT00838370
Drug: Capecitabine, 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients.
Study: NCT03238963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT01614041
Drug: Usual dose treatment of Tandospirone
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose treatment of Tandospirone, oral, 30 mg/day
Study: NCT01614041
Drug: Comparative high dose of tandospirone treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative high dose of tandospirone treatment, oral, 60 mg/day
Study: NCT00798434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered orally in the morning or evening.
Study: NCT01647945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT01647945
Drug: FK506 level < 2 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 goal trough blood level \< 2 ng/ml
Study: NCT01647945
Drug: FK506 level 2-3 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 goal trough blood level 2-3 ng/ml
Study: NCT01647945
Drug: FK506 level 3-5 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 goal trough blood level 3-5 ng/ml
Study: NCT02074904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02842541
Drug: EBI-031
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03542110
Drug: Matching Placebo subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, pre-filled, disposable, subcutaneous injection pen
Study: NCT02502747
Drug: optimal standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal standard of care
Study: NCT02960503
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
Study: NCT03659162
Drug: Azole Antifungal
Normalized name: Azole antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral gel \& injections
Study: NCT04395170
Drug: Standard (specific) therapy for COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.
Study: NCT01762332
Drug: Base level of remifentanil effect side concentration: 4ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
Study: NCT01156740
Drug: Penicillin G, Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg)
Study: NCT00974519
Drug: Fuzheng 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT00974519
Drug: Fuzheng 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT00974519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT02271984
Drug: MSC2499550A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
Study: NCT02271984
Drug: Cysticide
Normalized name: Crystacide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT02271984
Drug: MSC2499550A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT02271984
Drug: MSC2499550A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT02271984
Drug: MSC2499550A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT02271984
Drug: MSC2499550A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT03038035
Drug: MLC901
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks intervention with orally MLC901. 2 capsules 3 times a day
Study: NCT03038035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks intervention with orally placebo. 2 capsules 3 times a day
Study: NCT03289559
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03289559
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02749097
Drug: SHR0534
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02749097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00641680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00777075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03651557
Drug: Neu2000KWL High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
Study: NCT03651557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
Study: NCT03415243
Drug: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters \[mcL\]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel \[MBq\] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
Study: NCT03415243
Drug: Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi\[4MBq\]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
Study: NCT00078338
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
Study: NCT00078338
Drug: Copaxone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
Study: NCT01245140
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to receive verum (20 patients)
Study: NCT01245140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to receive placebo (10 patients)
Study: NCT00005977
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005977
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02340520
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00005977
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005977
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01483144
Drug: Sulindac 150 MG
Normalized name: sulindac 150 MG
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac \[one tablet orally once a day\]
Study: NCT01483144
Drug: Sulindac placebo
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac placebo \[one tablet orally once a day\]
Study: NCT03818126
Drug: del Nido cardioplegia
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit.
Study: NCT03818126
Drug: cold blood cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius.
Study: NCT02883595
Drug: thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Study: NCT03896659
Drug: Hydrocortisone Oral
Normalized name: hydrocortisone Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 160 mg tablet
Study: NCT03896659
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone-matched Placebo tablet
Study: NCT02530710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00421655
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.
Study: NCT01810939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00960362
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
Study: NCT00484822
Drug: Heparina Cálcica
Normalized name: Heparina
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.000 UI/día.
Study: NCT03499626
Drug: ASLAN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD
Study: NCT00844337
Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
Study: NCT02204293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered subcutaneously.
Study: NCT00196469
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193479
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT02932930
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,2ml/kg of 0.9% normal saline
Study: NCT00731133
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg/day
Study: NCT00945672
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered every 90 days or monthly to match experimental treatment arms.
Study: NCT00476073
Drug: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00913549
Drug: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00786474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution, dosage determined by weight, self-administered by patient twice a day
Study: NCT01395004
Drug: GSK2110183
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2110183 was orally administered at 125 mg once daily.
Study: NCT03994731
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral MTX 15 mg weekly
Study: NCT02532322
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Study: NCT03994731
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for MTX
Study: NCT03994731
Drug: gout flare prophylaxis regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
Study: NCT03994731
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
Study: NCT02532322
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Study: NCT04370015
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
Study: NCT01199068
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017 from 0.25 mg to 0.50 mg twice daily
Study: NCT05770960
Drug: codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
Study: NCT01277692
Drug: GSK2336805 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose once daily
Study: NCT01277692
Drug: GSK2336805 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose once daily
Study: NCT01277692
Drug: GSK2236805 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose once daily
Study: NCT01277692
Drug: GSK2236805 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose once daily
Study: NCT01277692
Drug: GSK2236805 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeat dose once daily for 7 days
Study: NCT01277692
Drug: GSK2236805 dose to be determined up to 100mg
Normalized name: Born To Be Mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeat dose once daily for 7 days
Study: NCT01277692
Drug: GSK2236805 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose in HCV infected patients
Study: NCT01277692
Drug: GSK2236805 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose in HCV infected patients
Study: NCT01277692
Drug: GSK2236805 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose in HCV infected patients
Study: NCT00003704
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00424034
Drug: GSK1325760A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00374036
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan
Study: NCT04727138
Drug: EXS21546 Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXS21546 Powder for Oral Suspension
Study: NCT04727138
Drug: EXS21546 Granule in Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXS21546 Granule in Capsule
Study: NCT02514681
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03471858
Drug: Prostaglandins
Normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin G2 (DB03866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostin will be used in the control arm.
Study: NCT02954978
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study: NCT02977286
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet po (enteral) twice daily
Study: NCT02977286
Drug: Senna 217 Mg Oral Tablet
Normalized name: senna 217 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.